Welcome!

News Feed Item

Final Day of the 2014 BIO International Convention to Feature the Annual Scientific American WorldView Scorecard, BIO Idea Hackathon and Look at FDA’s Critical Path Initiative

The 2014 BIO International Convention, the world’s largest biotechnology event, enters its fourth and final day today at the San Diego Convention Center. Hosted by the Biotechnology Industry Organization, this year’s event is expected to attract more than 3,000 biotechnology companies and more than 15,000 attendees from 48 states and 65 countries.

Upcoming Convention Highlights Include:

  • Super Session: Scientific American WorldView Super Session - Biotech: We are the World, Thursday, June 26
    What is happening in biotechnology and life science development on the global stage? What are the most pressing issues of our time that have every nation looking to science as a solution? As the world continues to flatten, individual countries are finding new ways to grow their innovation engines, and in some cases, are hoping to outshine the US. Come to the annual Scientific American WorldView super session to hear a dynamic panel of international industry luminaries examine the future of global innovation in a lively candid conversation. Moderated by television and radio journalist, David Brancaccio, host of Marketplace Morning Report, this session will explore key themes from Scientific American’s annual biotechnology edition, featuring the WorldView Scorecard and fresh perspectives on international life science development.
  • Super Session: The Next Big Deal: The Global Dealmaker Perspective, Thursday, June 26
    2013 delivered in a big way for each of the major deal-making outlets with nearly three times the number of IPOs as in 2012. The M&A market opened up with the total dollars spent on acquisitions reaching the highest in five years. Strong deal terms with large upfront payments for early stage assets were also seen in 2013 as exemplified with Moderna’s $240M upfront from Astrazeneca and Oncomed’s $177M upfront from Celgene. Will these upward trends continue? How will these changing dynamics impact dealmaking in the coming year? What do dealmakers expect will be the result in 2014? Campbell Alliance and BIO are pleased to present updated findings from two unique forward-looking measures of dealmaking in the industry – the Campbell Alliance Dealmakers’ Intentions Study and the BIO One-on-One Partnering Forecast. Based on a survey of more than 150 industry executives, business development professionals, and financial institutions, Dealmakers’ Intentions provides insight into what will likely drive the industry’s partnering and M&A efforts moving forward, and the implications for deal-making over the next year or more. Now in its sixth year, new analysis in 2014 will include year-over-year trends, additional deal metrics, and broader M&A data. Incorporating a global perspective, a highly distinguished panel of dealmakers will then explore the impact these market forces will have on pharmaceutical and biotech companies as they position themselves to make that next big deal.
  • New Technologies to Save Us In a Disaster: Opportunities in the Public-Private Partnership to Develop Medical Countermeasures, Thursday, June 26
    In the decade since the US Congress adopted Project Bioshield, more than $5 billion has been invested in the biodefense sector. This session will explore recent trends and new developments in the advanced development of medical countermeasures (MCMs). The session will provide an update on the status of the Centers of Innovation for Advanced Development and Manufacture and opportunities for drug developers. It will also provide perspectives on the need for novel technologies and key considerations for companies entering the biodefense sector as it matures.
  • The Salford Lung Study: An Innovative 'Real World' Study Design for Chronic Conditions, Thursday, June 26
    The 12-month Salford (UK) Lung Study uses an integrated electronic patient record to assess the safety and effectiveness of Relovair, GlaxoSmithKline's late-phase follow-up to Advair, in chronic obstructive pulmonary disease and asthma. Results are intended to help healthcare decision- makers better assess the drug's potential at an earlier stage. The panel will address the complexities of “real-world” studies and how healthcare providers and regulators can use the data generated to understand the benefits of such studies, particularly for chronic conditions managed in community settings.
  • FDA's Critical Path Initiative: Progress in the First Decade and Promise for the Next, Thursday, June 26
    In 2004, the FDA launched the Critical Path Initiative (CPI), which was a response to the needs and challenges faced by medical product developers. Recognizing that no one organization possesses the resources and expertise to solve medical product development problems, the CPI called for a consortium or public-private-partnership approach to modernize the process whereby FDA-regulated products are developed and evaluated. A brief videotaped overview of the CPI will be provided by its chief architect, Dr. Janet Woodcock (CDER/FDA). Then speakers from the FDA, and industry and non-profit organizations will reflect on certain aspects of CPI that have been accomplished through consortia, present the challenges faced by organizations working in the "pre-competitive" space, and explore options for optimizing future collaborations.
  • Biotech Battle of the Wits 2014, Thursday, June 26
    Back for its third year, well-known biotech journalist Chris Morrison will emcee this rapid-fire, interactive debate on the industry’s hot-button issues featuring three biotech trendsetters. Listen as panelists provide their off-the-cuff opinions on the industry’s most controversial and topical issues. What is the strangest biotech idea you’ve come across? How can a company bounce back from a Phase III failure? To drive the debate, audience members can ask questions live or via Twitter (@BioBanter) and vote for presenters online via Twitter or text. The winner of this session will receive 120 uninterrupted seconds to sound off on the topic of their choice.
  • BIO Career Fair, Thursday, June 26
    The 2014 BIO Career Fair is free to all job seekers. Co-located with the 2014 BIO International Convention, the BIO Career Fair will give attendees access to many of the world’s leading life science companies.

Day Three Session Highlights Included:

Follow the 2014 Convention @BIOConvention, and join the conversation @IAmBIOtech.

The Convention program features more than 160 sessions in 8 breakout sessions and 9 specialty forums. The majority of attendees, 70 percent, are c-level executives. They split evenly from large companies of 500 or more employees and small companies of 50 employees or less.

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on major trends affecting the industry. The Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. Visit http://convention.bio.org/program/ for the most up-to-date program and speaker information.

The Convention also features the BIO Business Forum, which has grown over the past thirteen years to become the industry's largest partnering event. This year’s Convention is set to break all previous partnering records, with over 28,000 meetings expected to take place. Powered by BIO's One-on-One Partnering™ System, the BIO Business Forum™ fosters the opportunity for companies to initiate business contacts in a friendly environment and schedule private meetings prior to the Convention.

Upcoming BIO Events

BIO Latin America Conference
September 9-11, 2014
Rio de Janeiro, Brazil

Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

For more information:
Visit http://www.bio.org
Follow us on Twitter @IAmBiotech
Join us on LinkedIn/MyBio
Become a fan at facebook.com/IAmBiotech

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Cloud Expo, Inc. has announced today that Andi Mann returns to 'DevOps at Cloud Expo 2017' as Conference Chair The @DevOpsSummit at Cloud Expo will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "DevOps is set to be one of the most profound disruptions to hit IT in decades," said Andi Mann. "It is a natural extension of cloud computing, and I have seen both firsthand and in independent research the fantastic results DevOps delivers. So I am excited to help the great t...
We are always online. We access our data, our finances, work, and various services on the Internet. But we live in a congested world of information in which the roads were built two decades ago. The quest for better, faster Internet routing has been around for a decade, but nobody solved this problem. We’ve seen band-aid approaches like CDNs that attack a niche's slice of static content part of the Internet, but that’s it. It does not address the dynamic services-based Internet of today. It does...
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, Dave McCarthy, Director of Products at Bsquare Corporation; Alan Williamson, Principal...
"Venafi has a platform that allows you to manage, centralize and automate the complete life cycle of keys and certificates within the organization," explained Gina Osmond, Sr. Field Marketing Manager at Venafi, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We analyze the video streaming experience. We are gathering the user behavior in real time from the user devices and we analyze how users experience the video streaming," explained Eric Kim, Founder and CEO at Streamlyzer, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"ReadyTalk is an audio and web video conferencing provider. We've really come to embrace WebRTC as the platform for our future of technology," explained Dan Cunningham, CTO of ReadyTalk, in this SYS-CON.tv interview at WebRTC Summit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
Regulatory requirements exist to promote the controlled sharing of information, while protecting the privacy and/or security of the information. Regulations for each type of information have their own set of rules, policies, and guidelines. Cloud Service Providers (CSP) are faced with increasing demand for services at decreasing prices. Demonstrating and maintaining compliance with regulations is a nontrivial task and doing so against numerous sets of regulatory requirements can be daunting task...
"We are a modern development application platform and we have a suite of products that allow you to application release automation, we do version control, and we do application life cycle management," explained Flint Brenton, CEO of CollabNet, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Dataloop.IO, an innovator in cloud IT-monitoring whose products help organizations save time and money, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Dataloop.IO is an emerging software company on the cutting edge of major IT-infrastructure trends including cloud computing and microservices. The company, founded in the UK but now based in San Fran...
Application transformation and DevOps practices are two sides of the same coin. Enterprises that want to capture value faster, need to deliver value faster – time value of money principle. To do that enterprises need to build cloud-native apps as microservices by empowering teams to build, ship, and run in production. In his session at @DevOpsSummit at 19th Cloud Expo, Neil Gehani, senior product manager at HPE, discussed what every business should plan for how to structure their teams to delive...
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Phil Hombledal, Solution Architect at CollabNet, discussed how customers are able to achieve a level of transparency that e...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
CloudJumper, a Workspace as a Service (WaaS) platform innovator for agile business IT, has been recognized with the Customer Value Leadership Award for its nWorkSpace platform by Frost & Sullivan. The company was also featured in a new report(1) by the industry research firm titled, “Desktop-as-a-Service Buyer’s Guide, 2016,” which provides a comprehensive comparison of DaaS providers, including CloudJumper, Amazon, VMware, and Microsoft.